Benefits of aldosterone receptor antagonism in chronic kidney disease (BARACK D) trial-a multi-centre, prospective, randomised, open, blinded end-point, 36-month study of 2,616 patients within primary care with stage 3b chronic kidney disease to compare the efficacy of spironolactone 25 mg once daily in addition to routine care on mortality and cardiovascular outcomes versus routine care alone: study protocol for a randomized controlled trial
Hill NR, Lasserson D, Thompson B, Perera-Salazar R, Wolstenholme J, Bower P, Blakeman T, Fitzmaurice D, Little P, Feder G, Qureshi N, Taal M, Townend J, Ferro C, McManus R, Hobbs FR
Record ID 32013000954
English
Original Title:
Benefits of aldosterone receptor antagonism in chronic kidney disease (BARACK D) trial
Details
Project Status:
Ongoing
URL for project:
https://www.journalslibrary.nihr.ac.uk/programmes/hta/120152/#/
URL for protocol:
https://pubmed.ncbi.nlm.nih.gov/24886488/ and correction: https://pubmed.ncbi.nlm.nih.gov/36510220/
Anticipated Publish Date:
2022
Requestor:
NIHR Health Technology Assessment programme
English language abstract:
An English language summary is available
Publication Type:
Full HTA
Country:
England, United Kingdom
MeSH Terms
- Mineralocorticoid Receptor Antagonists
- Kidney Failure, Chronic
- Aldosterone
- Renal Insufficiency, Chronic
- Spironolactone
Contact
Organisation Name:
NIHR Health Technology Assessment programme
Contact Address:
NIHR Journals Library, National Institute for Health and Care Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton SO16 7NS, UK
Contact Name:
journals.library@nihr.ac.uk
Contact Email:
journals.library@nihr.ac.uk
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.